JNJ-9220 / J&J - LARVOL DELTA

Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial. (PubMed, Lancet HIV) - P3 | "The lack of efficacy in this and other HIV vaccine trials points to the importance of current efforts to develop vaccines that generate broadly neutralising antibodies."

Clinical • Journal • P3 data • Allergy • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Thrombocytopenia • Thrombosis

Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trial. (PubMed, EBioMedicine) - "Our study introduces an innovative analysis approach to identify vaccine-induced T cell subpopulations in vaccine trials. Comparison of T cell clusters between cases and controls holds promise for improving the efficacy of future HIV-1 vaccination strategies."

Journal • Allergy • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • CD4 • CD8

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (clinicaltrials.gov) - P1/2 | N=201 | Completed | Sponsor: Janssen Vaccines & Prevention B.V. | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Immunology • Infectious Disease • IFNG • IL2 • IL4 • TNFA

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (clinicaltrials.gov) - P1/2 | N=201 | Active, not recruiting | Sponsor: Janssen Vaccines & Prevention B.V. | Trial completion date: Apr 2023 ➔ May 2022

Trial completion date • Human Immunodeficiency Virus • Immunology • Infectious Disease • IFNG • IL2 • IL4 • TNFA

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). (PubMed, Lancet HIV) - P1 | "Short, 6-month regimens of a mosaic HIV-1 prophylactic vaccine elicited robust HIV-specific immune responses that were similar to responses elicited by a longer, 12-month schedule. Preclinical data showed partial protective efficacy of one of the short vaccine regimens in rhesus monkeys. Further clinical studies are required to test the suitability of the shortened vaccine regimens in humans. Such shortened regimens would be valuable to increase vaccine delivery at the community level, particularly in resource-limited settings."

Journal • P1 data • Fatigue • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Pain

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment (clinicaltrials.gov) - P1; N=25; Active, not recruiting; Sponsor: Janssen Vaccines & Prevention B.V.; Trial primary completion date: Oct 2020 ➔ Nov 2021

Clinical • Trial primary completion date • Human Immunodeficiency Virus • Immunology • Infectious Disease

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment (clinicaltrials.gov) - P1; N=25; Active, not recruiting; Sponsor: Janssen Vaccines & Prevention B.V.; Recruiting ➔ Active, not recruiting; Trial primary completion date: Mar 2020 ➔ Oct 2020

Clinical • Enrollment closed • Trial primary completion date • Gene Therapies • Human Immunodeficiency Virus • Infectious Disease

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment (clinicaltrials.gov) - P1; N=26; Recruiting; Sponsor: Janssen Vaccines & Prevention B.V.; Trial completion date: Feb 2021 ➔ Feb 2022

Clinical • Trial completion date